Pancreatic Cancer Biomarkers
BRCA1/BRCA2 testing is critical for all pancreatic cancer patients — if you carry a BRCA mutation, the PARP inhibitor olaparib is FDA-approved as a maintenance therapy after first-line chemotherapy.
Reviewed by XpertPatient Medical Advisory · Updated June 2026 · Sources: NCI · ACS · ASCO · NIH/PMC
Start Here
What is a biomarker?
A biomarker in pancreatic cancer is a measurable signal — in your blood or tumor tissue — that tells your doctor about your cancer’s specific biology. CA 19-9 is a protein that pancreatic cancer cells release into the blood. BRCA and KRAS are gene mutations found in the tumor itself.
Pancreatic cancer has historically had few treatment options. But for patients with BRCA mutations — found in 5–7% of cases — a targeted drug called olaparib is now FDA-approved. This makes biomarker testing essential for every pancreatic cancer patient, regardless of family history.
What this means for you: Every pancreatic cancer patient should have both tumor testing (somatic) and inherited gene testing (germline). The results matter for your treatment — and for your family members.
The Tests Your Doctor Orders
🔍 Do you have an inherited gene mutation that also affects treatment?
BRCA mutations are found in 5–7% of pancreatic cancer patients. If you have one AND your cancer responded to platinum-based chemotherapy, olaparib (Lynparza) is FDA-approved as a maintenance therapy. Ask your doctor if you’ve been tested.
🔍 Is a protein released by pancreatic cancer cells elevated in your blood?
CA 19-9 is the main blood marker for pancreatic cancer. A falling CA 19-9 usually means treatment is working. Note: about 10% of people can’t produce CA 19-9 at all — if that’s you, this test won’t be useful as a tracking tool.
🔍 Is there a common driver mutation in your tumor?
KRAS mutations are present in over 90% of pancreatic cancers. New drugs targeting specific KRAS mutations are now in clinical trials. Ask your doctor about KRAS inhibitor trials if standard treatments haven’t worked.
Watch & Learn
Common Questions
Pancreatic Cancer Biomarkers — Your Questions Answered
Should every pancreatic cancer patient get BRCA testing?
Yes. Guidelines recommend genetic testing for all patients with pancreatic ductal adenocarcinoma, regardless of age or family history. Even a small chance of finding a BRCA mutation is worth it — it can change your treatment options.
How does olaparib work?
Olaparib blocks a DNA repair mechanism that BRCA-mutated cancer cells depend on. Without it, cancer cells can’t repair their DNA and they die. It’s approved as maintenance therapy after platinum-based chemotherapy in BRCA-mutated pancreatic cancer.
What if my CA 19-9 isn’t elevated?
About 10% of people are ‘Lewis antigen-negative’ and can’t produce CA 19-9. If this is you, your doctor will use imaging and other markers to track your disease instead.
Are there clinical trials for KRAS?
Yes — this is one of the most active research areas in pancreatic cancer. KRAS inhibitors that were recently approved in lung cancer are being studied in pancreatic cancer. Ask your oncologist or visit clinicaltrials.gov.
Know Your Biomarkers. Own Your Journey.
Free, survivor-led cancer education for newly diagnosed patients.
Visit the Pancreatic Cancer Center → Full Biomarkers Guide →
